Compile Data Set for Download or QSAR
Report error Found 92 Enz. Inhib. hit(s) with all data for entry = 2302
TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360809(US9828396, Compound 58 | 1-(2-((1R,3S,5R)-3-(6- br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360820(US9828396, Compound 69 | 1-(2-((2S,4R)-4-fluoro-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360819(US9828396, Compound 68 | 1-(2-((2S,4R)-2-(5- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360818(US9828396, Compound 67 | 1-(2-((2S,4R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360817(US9828396, Compound 66 | (S)-3-(2-(3-carbamoyl-5- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360816(US9828396, Compound 65 | 1-(2-((1R,3S,5R)-3-(6- br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360815(US9828396, Compound 64 | 1-(2-((1R,3S,5R)-3-(2'- c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360814(US9828396, Compound 63 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360813(US9828396, Compound 62 | 1-(2-((1R,3S,5R)-3-(6- fl...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360812(US9828396, Compound 61 | 1-(2-((1R,3S,5R)-3-(6- br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360811(US9828396, Compound 60 | 1-(2-((1R,3S,5R)-3-(6- br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360810(US9828396, Compound 59 | 1-(2-((1R,3S,5R)-3-(6- br...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360821(US9828396, Compound 70 | 1-(2-((2S,4R)-4-fluoro-2-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360808(US9828396, Compound 57 | 1-(2-((1R,3S,5R)-3-(6- cy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360807(US9828396, Compound 56 | 1-(2-((1R,3S,5R)-3-(6- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360806(US9828396, Compound 55 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360805(US9828396, Compound 54 | 1-(2-((1R,3S,5R)-3-(6- cy...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360804(US9828396, Compound 53 | 1-(2-((1R,3S,5R)-3-(2'- c...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360803(US9828396, Compound 52 | 1-(2-((2S,3R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360801(US9828396, Compound 50 | 1-(2-((2S,4R)-2-(6-(1H- p...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360800(US9828396, Compound 49 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360799(US9828396, Compound 48 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360752(US9828396, Compound 1 | (2S,4R)-1-(2-(3-acetyl-6- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360832(US9828396, Compound 81 | 1-(2-((2S,4R)-2-(6-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360843(US9828396, Compound 92 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360842(US9828396, Compound 91 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360841(US9828396, Compound 90 | (2S,4R)-1-(2-(3-acetyl-5-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360840(US9828396, Compound 89 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360839(US9828396, Compound 88 | 1-(2-((2S,4R)-2-(6- chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360838(US9828396, Compound 87 | 1-(2-((2S,4R)-2-(6-(2- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360837(US9828396, Compound 86 | 1-(2-((2S,4R)-2-(6-(2- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360836(US9828396, Compound 85 | 1-(2-((2S,4R)-2-(6-(2- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360835(US9828396, Compound 84 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360834(US9828396, Compound 83 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360833(US9828396, Compound 82 | 1-(2-((2S,4R)-2-(6- chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360798(US9828396, Compound 47 | 1-(2-((2S,4R)-2-(6-(2- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360831(US9828396, Compound 80 | 1-(2-((2S,4R)-2-(6- chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360830(US9828396, Compound 79 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360829(US9828396, Compound 78 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360828(US9828396, Compound 77 | 1-(2-((1R,3S,5R)-3-(6- ch...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360827(US9828396, Compound 76 | 1-(2-((2S,4R)-2-(6-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360826(US9828396, Compound 75 | 1-(2-((2S,4R)-2-(6- chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360825(US9828396, Compound 74 | 1-(2-((2S,4R)-2-(6-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360824(US9828396, Compound 73 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360823(US9828396, Compound 72 | 5-((5-fluoropyrimidin-2- ...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360822(US9828396, Compound 71 | 1-(2-((2S,4R)-2-(8- chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360764(US9828396, Compound 13 | (2S,4R)-1-(2-(3-acetyl-5-...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360797(US9828396, Compound 46 | 1-(2-((2S,4R)-2-(6- bromo...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360774(US9828396, Compound 23 | 1-(2-((2S,4R)-2-(3-chloro...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

TargetComplement factor D(Human)
Achillion Pharmaceuticals

US Patent
LigandPNGBDBM360773(US9828396, Compound 22 | 1-(2-((2S,4R)-2-(2'-chlor...)
Affinity DataIC50: 1.00E+3nMAssay Description:Human factor D (purified from human serum, Complement Technology, Inc.) at 80 nM final concentration is incubated with test compound at various conce...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/22/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 92 total ) | Next | Last >>
Jump to: